Efficacy and Plasma Drug Concentrations With Nondaily Dosing of Rosuvastatin
Authors:
- Marianne K. DeGorterMDMarianne K. DeGorter
- Matthew R. BanMBMatthew R. Ban
- Richard B. KimRKRichard B. Kim
- Robert A. HegeleRHRobert A. Hegele
- 1 August 2013
- journal article
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 29 (8) , 915-919
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Disposition of Atorvastatin, Rosuvastatin, and Simvastatin in Oatp1b2‐/‐ Mice and Intraindividual Variability in Human SubjectsThe Journal of Clinical Pharmacology, 2012
- Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational studyCurrent Medical Research and Opinion, 2012
- Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus ConferenceCanadian Journal of Cardiology, 2011
- Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intoleranceJournal of Clinical Lipidology, 2011
- Statin-Associated Rhabdomyolysis: Is There a Dose-Response Relationship?Canadian Journal of Cardiology, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Efficacy of Rosuvastatin (5 mg and 10 mg) Twice a Week in Patients Intolerant to Daily StatinsThe American Journal of Cardiology, 2008
- Genetic determinants of statin intoleranceLipids in Health and Disease, 2007
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)The American Journal of Cardiology, 2003
- Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.The American Journal of Cardiology, 2001